Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03989622
Other study ID # I15007
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2019
Est. completion date June 2023

Study information

Verified date April 2019
Source University Hospital, Limoges
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Retinopathy pigmentosa (which affects about 40,000 patients in France) leads to destruction of the peripheral retina. This condition, often familial, frequently affects young patients. Visual acuity is excellent for a long time, the disease affecting the central macular region only belatedly. On the other hand, the visual field is very quickly narrowed to a central or paracentral zone.

For the patient, knowing the limits of his visual field and learning to adapt is necessary especially when traveling.

The management of these patients is twofold:

- an orthoptist carries out an overall evaluation of the visual field using the Goldmann device (30 cm projection of the areas seen and not seen by the patient's eye), then performs rehabilitation over several weeks

- an instructor of locomotion (open specialization: occupational therapist, case of this project,...) carries out an evaluation in situation, followed by a personalized reeducation over several weeks. The first sessions consist in establishing a climate of confidence, presenting the objectives of the management of locomotion and begin to understand the movements inside and outside accompanied. The following of the rehabilitation is an apprenticeship of the optimal use of the residual field of vision and the proposed technical aids (white cane), in the whole of the displacements, inside and outside.

The residual field of vision is evaluated by a device at the first appointment at the specialized center. This examination, necessary for the professional, is not informative for the patient. It is sometimes supplemented by the evaluation of the visual field of view (ECVS). The ECVS, done jointly by the orthoptist and the locomotion instructor, consists in evaluating the functional visual field on a horizontal plane at 1m (meter) and 5m, and vertical at 5m. The field of vision of the patient, immobile, is materialized by targets deposited at each limit of the zones seen that it indicates.

The investigators believe that the passing of a visual field on the ground, thanks to the projection of the zones of vision, allows the patient to improve his knowledge on his visual possibilities (and gaps) and thus to make his reeducation more efficient.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 52
Est. completion date June 2023
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patient at least 18 years old

- patient with retinitis pigmentosa

- a visual field less than or equal to 20 degrees regardless of the degree of visual acuity

- lack of peripheral islets

- to be able to move without a white detection cane

- have signed an informed consent

- be an affiliate or beneficiary of a French social security system.

Exclusion Criteria:

- severe disorders of transparent media that may interfere with visual impairment related to retinitis pigmentosa

- impossibility to follow the protocol

- Limitation of locomotion activities related to other than visual impairments: neurological disorders (hemiplegia, neuropathy, ...)

- musculoskeletal disorders (arthropathies ...)

- Any participation in a protocol having an impact on the walking path by Virtual Reality

- person under the protection of justice, or under guardianship or curators

- pregnant or lactating woman

Study Design


Intervention

Other:
evaluation of the visual field on the ground
evaluation of the visual field on the ground

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Limoges

Outcome

Type Measure Description Time frame Safety issue
Primary difference in the number of errors committed during a walk between T0 and T2 difference in the number of errors committed (= number of hurdles, number of "doors" forgotten) during a walk between T0 (before ECVS) and T2 (after ECVS + 10 re-education sessions). 2 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05392751 - Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa Phase 1/Phase 2